TME Pharma NV (XPAR:ALTME) Ending Cash Position: €2.01 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALTME TME Pharma NV XPAR:ALTME
23 GF Score
Price €0.13
! 4 Warning Signs
View Full Analysis

What is TME Pharma NV Ending Cash Position?

TME Pharma NV XPAR:ALTME +11.61% 23 Ending Cash Position is €2.01 Mil as of Dec. 2025. GuruFocus rates XPAR:ALTME with a GF Score™ of 23/100. The stock has 4 warning signs investors should review.

TME Pharma NV's Ending Cash Position for the quarter that ended in Dec. 2025 was €2.01 Mil.

TME Pharma NV's quarterly Ending Cash Position declined from Dec. 2024 (€3.24 Mil) to Jun. 2025 (€2.06 Mil) and declined from Jun. 2025 (€2.06 Mil) to Dec. 2025 (€2.01 Mil).

TME Pharma NV's annual Ending Cash Position increased from Dec. 2023 (€2.25 Mil) to Dec. 2024 (€3.24 Mil) but then declined from Dec. 2024 (€3.24 Mil) to Dec. 2025 (€2.01 Mil).

TME Pharma NV Ending Cash Position Related Terms

TME Pharma NV Ending Cash Position Historical Data

* Premium members only.

The historical data trend for TME Pharma NV's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TME Pharma NV Ending Cash Position Chart

TME Pharma NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.46 4.63 2.25 3.24 2.01

TME Pharma NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.25 2.70 3.24 2.06 2.01
XPAR:ALTME
23GF Score
TME Pharma NV XPAR:ALTME
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TME Pharma NV Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

TME Pharma NV's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3.24+-1.228
=2.01

TME Pharma NV's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2.06+-0.048
=2.01

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €2.01 Mil mean?
TME Pharma NV (XPAR:ALTME) has a Ending Cash Position of €2.01 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on TME Pharma NV and its competitors.
Is TME Pharma NV's Ending Cash Position too high?
TME Pharma NV's current Ending Cash Position is €2.01 Mil. Overall, TME Pharma NV has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does TME Pharma NV's Ending Cash Position compare to VRTX and REGN?
TME Pharma NV's Ending Cash Position of €2.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on TME Pharma NV and its competitors. TME Pharma NV's current Ending Cash Position is €2.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current Ending Cash Position of €2.01 Mil. The current Ending Cash Position is €2.01 Mil. TME Pharma NV's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current Ending Cash Position is €2.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TME Pharma NV Business Description

Other Exchanges 0N6A:Germany
Address Max-Dohrn-Strasse 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.
23GF Score

Get the complete analysis for XPAR:ALTME

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price